{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:44:07Z","timestamp":1778615047984,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T00:00:00Z","timestamp":1348444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T00:00:00Z","timestamp":1348444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1038\/bmt.2012.175","type":"journal-article","created":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T07:06:48Z","timestamp":1348470408000},"page":"278-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant"],"prefix":"10.1038","volume":"48","author":[{"given":"S K","family":"Khaled","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Stiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Senitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Maegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P M","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Nademanee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-L","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D S","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Karanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S H","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S J","family":"Forman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,24]]},"reference":[{"key":"BFbmt2012175_CR1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood.V86.2.813.bloodjournal862813","volume":"86","author":"A Gratwohl","year":"1995","unstructured":"Gratwohl A, Hermans J, Apperley J, Arcese W, Bacigalupo A, Bandini G et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood 1995; 86: 813\u2013818.","journal-title":"Blood"},{"key":"BFbmt2012175_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/bbmt.2002.v8.pm11846354","volume":"8","author":"SJ Lee","year":"2002","unstructured":"Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S, Antin JH et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant 2002; 8: 32\u201339.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012175_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbmt.2003.12.305","volume":"10","author":"C Cutler","year":"2004","unstructured":"Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 328\u2013336.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012175_CR4","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1182\/blood-2007-01-069294","volume":"110","author":"FM Marty","year":"2007","unstructured":"Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110: 490\u2013500.","journal-title":"Blood"},{"key":"BFbmt2012175_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.bbmt.2005.02.006","volume":"11","author":"C Cutler","year":"2005","unstructured":"Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383\u2013388.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012175_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1182\/blood-2009-03-207563","volume":"115","author":"R Rodriguez","year":"2010","unstructured":"Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A et al. A phase II pilot study of tacrolimus\/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010; 115: 1098\u20131105.","journal-title":"Blood"},{"key":"BFbmt2012175_CR7","first-page":"643","volume":"4","author":"A Kessinger","year":"1989","unstructured":"Kessinger A, Smith DM, Strandjord SE, Landmark JD, Dooley DC, Law P et al. Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989; 4: 643\u2013646.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2012175_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1600-0609.2011.01692.x","volume":"87","author":"J Auberger","year":"2011","unstructured":"Auberger J, Clausen J, Kropshofer G, Kircher B, Lindner B, Nachbaur D . Allogeneic bone marrow versus peripheral blood stem cell transplantation: a long-term retrospective single-centre analysis in 329 patients. Eur J Haematol 2011; 87: 531\u2013538.","journal-title":"Eur J Haematol"},{"key":"BFbmt2012175_CR9","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood.V98.6.1739","volume":"98","author":"M Remberger","year":"2001","unstructured":"Remberger M, Ringden O, Blau IW, Ottinger H, Kremens B, Kiehl MG et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739\u20131745.","journal-title":"Blood"},{"key":"BFbmt2012175_CR10","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.bbmt.2007.08.006","volume":"13","author":"M Eapen","year":"2007","unstructured":"Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007; 13: 1461\u20131468.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012175_CR11","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood.V99.4.1130.h8001130_1130_1135","volume":"99","author":"AH Elmaagacli","year":"2002","unstructured":"Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130\u20131135.","journal-title":"Blood"},{"key":"BFbmt2012175_CR12","first-page":"1","volume":"118","author":"C Anasetti","year":"2011","unstructured":"Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: results of blood and marrow transplant clinical trials network (BMT CTN) protocol 0201, a phase III, prospective, randomized trial. ASH 2011; 118: 1.","journal-title":"ASH"},{"key":"BFbmt2012175_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/bmt.2009.112","volume":"45","author":"R Rodriguez","year":"2010","unstructured":"Rodriguez R, Nademanee A, Palmer JM, Parker P, Nakamura R, Snyder D et al. Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD. Bone Marrow Transplant 2010; 45: 205\u2013207.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2012175_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295\u2013304.","journal-title":"Transplantation"},{"key":"BFbmt2012175_CR15","first-page":"545","volume":"91","author":"HM Shulman","year":"1978","unstructured":"Shulman HM, Sale GE, Lerner KG, Barker EA, Weiden PL, Sullivan K et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978; 91: 545\u2013570.","journal-title":"Am J Pathol"},{"key":"BFbmt2012175_CR16","unstructured":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 9 August 2006. Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"key":"BFbmt2012175_CR17","first-page":"1","volume":"82","author":"NE Breslow","year":"1987","unstructured":"Breslow NE, Day NE . Statistical methods in cancer research: volume II, the design and analysis of cohort studies. IARC Sci Publ 1987; 82: 1\u2013406.","journal-title":"IARC Sci Publ"},{"key":"BFbmt2012175_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695\u2013706.","journal-title":"Stat Med"},{"key":"BFbmt2012175_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/pbc.22861","volume":"57","author":"J Rosenthal","year":"2011","unstructured":"Rosenthal J, Pawlowska A, Bolotin E, Cervantes C, Maroongroge S, Thomas SH et al. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus. Pediatr Blood Cancer 2011; 57: 142\u2013146.","journal-title":"Pediatr Blood Cancer"},{"key":"BFbmt2012175_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1056\/NEJM198202183060703","volume":"306","author":"NK Ramsay","year":"1982","unstructured":"Ramsay NK, Kersey JH, Robison LL, McGlave PB, Woods WG, Krivit W et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982; 306: 392\u2013397.","journal-title":"N Engl J Med"},{"key":"BFbmt2012175_CR21","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","volume":"98","author":"A Bacigalupo","year":"2001","unstructured":"Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942\u20132947.","journal-title":"Blood"},{"key":"BFbmt2012175_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.bmt.1704758","volume":"35","author":"A Bacigalupo","year":"2005","unstructured":"Bacigalupo A . Antilymphocyte\/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005; 35: 225\u2013231.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2012175_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012175_CR24","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.bbmt.2010.09.017","volume":"17","author":"LL Rosenbeck","year":"2010","unstructured":"Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK et al. Prophylaxis with sirolimus and tacrolimus +\/- antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 17: 916\u2013922.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012175_CR25","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","volume":"12","author":"B George","year":"2010","unstructured":"George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010; 12: 322\u2013329.","journal-title":"Transpl Infect Dis"},{"key":"BFbmt2012175_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.bbmt.2010.08.007","volume":"17","author":"N Reddy","year":"2011","unstructured":"Reddy N, Rezvani K, Barrett AJ, Savani BN . Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 2011; 17: 591\u2013597.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2012175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2012175","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2012175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T11:22:15Z","timestamp":1648034535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2012175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,24]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["BFbmt2012175"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2012.175","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717958751.793462917","asserted-by":"object"}]},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,24]]},"assertion":[{"value":"3 April 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr R Nakamura and Dr R Rodriguez shared a $20\u2009000 research fund from Genzyme. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}